Inhibrx Biosciences, Inc.

INBX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
27
SEC Filings

Business Summary

. Overview We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. Recent Developme...

Next Earnings

Q2 FY2026 — expected 2026-08-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionINBXdiscussed_in_filing Cybersecurity
topic_mentionINBXdiscussed_in_filing Trusted Computing
topic_mentionINBXdiscussed_in_filing Blockchain & Crypto
topic_mentionINBXdiscussed_in_filing Regulation
topic_mentionINBXdiscussed_in_filing Healthcare & Bio
topic_mentionINBXdiscussed_in_filing Platform & Ecosystem
topic_mentionINBXdiscussed_in_filing Cybersecurity
topic_mentionINBXdiscussed_in_filing Trusted Computing
topic_mentionINBXdiscussed_in_filing Blockchain & Crypto
topic_mentionINBXdiscussed_in_filing Regulation
topic_mentionINBXdiscussed_in_filing Healthcare & Bio
topic_mentionINBXdiscussed_in_filing Platform & Ecosystem
topic_mentionINBXdiscussed_in_filing Cybersecurity
topic_mentionINBXdiscussed_in_filing Trusted Computing
topic_mentionINBXdiscussed_in_filing Blockchain & Crypto
topic_mentionINBXdiscussed_in_filing Regulation
topic_mentionINBXdiscussed_in_filing Healthcare & Bio
topic_mentionINBXdiscussed_in_filing Platform & Ecosystem
topic_mentionINBXdiscussed_in_filing Cybersecurity
topic_mentionINBXdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310002007919-26-000006EDGAR92K words
2025-03-172024-12-310002007919-25-000019EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300002007919-25-000093EDGAR23K words
2025-08-132025-06-300002007919-25-000081EDGAR—
2025-05-142025-03-310002007919-25-000056EDGAR—
2024-11-142024-09-300002007919-24-000058EDGAR—
2024-08-132024-06-300002007919-24-000029EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190002007919-26-000007EDGAR2K words
2026-02-230002007919-26-000002EDGAR—
2025-12-160002007919-25-000097EDGAR—
2025-11-140002007919-25-000094EDGAR—
2025-10-230002007919-25-000089EDGAR—
2025-08-130002007919-25-000083EDGAR—
2025-05-280002007919-25-000063EDGAR—
2025-05-140002007919-25-000057EDGAR—
2025-04-010002007919-25-000028EDGAR—
2025-03-170002007919-25-000020EDGAR—

27 total filings indexed. 10 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0002007919
TickerINBX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9cc9274fdef82d43ea3aa027aef4f6ade60a1f3db7046e1585be863a3d0489a0
parent: 8a505f6533a08299a78c21e401a254832fcbacb8afcff2176d66264fe0a09b9f
content hash: 3586c6e4429c6f566fb6108608a671c9cdbe8543f007cccff40faf6e73fba17c
signed: 2026-04-13T04:45:41.314Z
sources: 7 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf